HK1143744A1 - Conjugate comprising a selective estrogen receptor modulator and a ribosome inactivating toxin - Google Patents
Conjugate comprising a selective estrogen receptor modulator and a ribosome inactivating toxinInfo
- Publication number
- HK1143744A1 HK1143744A1 HK10110283.3A HK10110283A HK1143744A1 HK 1143744 A1 HK1143744 A1 HK 1143744A1 HK 10110283 A HK10110283 A HK 10110283A HK 1143744 A1 HK1143744 A1 HK 1143744A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- conjugate
- estrogen receptor
- receptor modulator
- selective estrogen
- ribosome inactivating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0718045.8A GB0718045D0 (en) | 2007-09-14 | 2007-09-14 | Pharmaceutical compound |
| PCT/EP2008/062071 WO2009034136A2 (en) | 2007-09-14 | 2008-09-11 | Pharmaceutical compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1143744A1 true HK1143744A1 (en) | 2011-01-14 |
Family
ID=38659041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK10110283.3A HK1143744A1 (en) | 2007-09-14 | 2010-11-03 | Conjugate comprising a selective estrogen receptor modulator and a ribosome inactivating toxin |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9056140B2 (xx) |
| EP (1) | EP2185204B1 (xx) |
| JP (1) | JP5478492B2 (xx) |
| CN (1) | CN101795712A (xx) |
| AU (1) | AU2008297129B2 (xx) |
| CA (1) | CA2699488C (xx) |
| ES (1) | ES2550937T3 (xx) |
| GB (1) | GB0718045D0 (xx) |
| HK (1) | HK1143744A1 (xx) |
| NZ (1) | NZ583160A (xx) |
| RU (1) | RU2455990C2 (xx) |
| WO (1) | WO2009034136A2 (xx) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2391358A1 (en) | 2009-01-27 | 2011-12-07 | Wisconsin Alumni Research Foundation | Therapeutic treatment of cancer and dysplasia of the cervix or vagina using estrogen antagonists |
| US20160000787A1 (en) * | 2013-02-26 | 2016-01-07 | Senex Biotechnology, Inc. | Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer |
| AU2020274113A1 (en) | 2019-05-14 | 2021-11-11 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| US11952349B2 (en) | 2019-11-13 | 2024-04-09 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| TW202304928A (zh) | 2021-03-23 | 2023-02-01 | 美商諾維雪碧歐公司 | 抗癌核荷爾蒙受體標靶化合物 |
| IL308104A (en) | 2021-05-03 | 2023-12-01 | Nuvation Bio Inc | Nuclear hormone receptor-targeted compounds against cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE62463B1 (en) * | 1988-07-07 | 1995-02-08 | Res Dev Foundation | Immunoconjugates for cancer diagnosis and therapy |
| US5478804A (en) | 1990-09-19 | 1995-12-26 | The Salk Institute For Biological Studies | Treatment of tumorigenic pathophysiological conditions with FGF-cytoxic conjugates |
| AU6446194A (en) | 1993-03-17 | 1994-10-11 | Whittier Institute For Diabetes And Endocrinology, The | Monoclonal antibodies specific for fibroblast growth factor receptors, immunotoxins, and use thereof |
| WO1996008274A2 (en) | 1994-09-13 | 1996-03-21 | Prizm Pharmaceuticals, Inc. | Conjugates of heparin-binding epidermal growth factor-like growth factor with targeted agents |
| US20010051348A1 (en) * | 2000-01-28 | 2001-12-13 | Lee Chee Wee | Novel ligands and methods for preparing same |
| AU2003275985A1 (en) | 2002-06-12 | 2003-12-31 | Research Development Foundation | Immunotoxin as a therapeutic agent and uses thereof |
| US7166691B2 (en) * | 2002-12-20 | 2007-01-23 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Saposin C and receptors as targets for treatment of benign and malignant disorders |
| TWI309571B (en) * | 2002-12-31 | 2009-05-11 | Ind Tech Res Inst | Delivery carrier for targeting cells haring over-expressed estrogen |
| NZ552476A (en) | 2004-06-10 | 2009-09-25 | Viventia Biotech Inc | Tumor specific antibody |
| AU2006210769A1 (en) * | 2005-02-01 | 2006-08-10 | Research Development Foundation | BLyS fusion proteins for targeting BLyS receptor and methods for treatment of B-cell proliferative disorders |
-
2007
- 2007-09-14 GB GBGB0718045.8A patent/GB0718045D0/en not_active Ceased
-
2008
- 2008-09-11 EP EP08804036.5A patent/EP2185204B1/en not_active Not-in-force
- 2008-09-11 US US12/677,701 patent/US9056140B2/en not_active Expired - Fee Related
- 2008-09-11 ES ES08804036.5T patent/ES2550937T3/es active Active
- 2008-09-11 CA CA2699488A patent/CA2699488C/en active Active
- 2008-09-11 NZ NZ583160A patent/NZ583160A/xx not_active IP Right Cessation
- 2008-09-11 AU AU2008297129A patent/AU2008297129B2/en not_active Ceased
- 2008-09-11 JP JP2010524488A patent/JP5478492B2/ja not_active Expired - Fee Related
- 2008-09-11 WO PCT/EP2008/062071 patent/WO2009034136A2/en active Application Filing
- 2008-09-11 RU RU2010114755/15A patent/RU2455990C2/ru not_active IP Right Cessation
- 2008-09-11 CN CN200880105602A patent/CN101795712A/zh active Pending
-
2010
- 2010-11-03 HK HK10110283.3A patent/HK1143744A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2185204B1 (en) | 2015-08-05 |
| WO2009034136A3 (en) | 2009-09-11 |
| JP2010539134A (ja) | 2010-12-16 |
| ES2550937T3 (es) | 2015-11-13 |
| AU2008297129B2 (en) | 2012-10-11 |
| CA2699488C (en) | 2013-06-18 |
| EP2185204A2 (en) | 2010-05-19 |
| GB0718045D0 (en) | 2007-10-24 |
| WO2009034136A2 (en) | 2009-03-19 |
| AU2008297129A1 (en) | 2009-03-19 |
| CN101795712A (zh) | 2010-08-04 |
| RU2455990C2 (ru) | 2012-07-20 |
| US20100286062A1 (en) | 2010-11-11 |
| US9056140B2 (en) | 2015-06-16 |
| CA2699488A1 (en) | 2009-03-19 |
| RU2010114755A (ru) | 2011-10-20 |
| JP5478492B2 (ja) | 2014-04-23 |
| NZ583160A (en) | 2012-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1212588A1 (zh) | 結合配體-接頭綴合物及其使用方法 | |
| EP2174845A4 (en) | AIRBAG AND AIR BAG DEVICE | |
| EP2180733A4 (en) | USER DEVICE, BASIC STATION AND CHANNEL CONFIGURATION PROCEDURE FOR UPSTREAM CONNECTION | |
| HK1143744A1 (en) | Conjugate comprising a selective estrogen receptor modulator and a ribosome inactivating toxin | |
| GB2441962B (en) | A support device | |
| GB2459073B (en) | A communication network and devices | |
| ZA200704223B (en) | Estrogen receptor modulators | |
| IL182829A0 (en) | Estrogen receptor modulators | |
| GB0613118D0 (en) | Controlling a mobile device | |
| PL2127457T3 (pl) | Adaptacja łącza w bezprzewodowym systemie telekomunikacyjnym | |
| EP2139243A4 (en) | BASE STATION, WIRELESS CONTROL ARRANGEMENT AND WIRELESS ARRANGEMENT | |
| GB0712263D0 (en) | A Combined toilet and seat apparatus | |
| EP2194282A4 (en) | SET OF BAND AND BAG | |
| EP2183678A4 (en) | SELECTION AND APPLICATION OF A COMMUNICATION VERSION | |
| EP2120653A4 (en) | DEVICE AND SYSTEM FOR PREPARING BEVERAGES | |
| EP2028064A4 (en) | AIRBAG AND AIRBAG DEVICE | |
| EP2218234A4 (en) | FIREWALL CONFIGURATION IN A BASE STATION | |
| HK1138799A1 (en) | Polyethylene glycol-g-csf conjugate | |
| EP2174840A4 (en) | AIRBAG AND AIR BAG DEVICE | |
| HK1125532A2 (en) | A paper-retaining device | |
| ZA200710492B (en) | Positioning device for a prosthesis device and system therefore | |
| IL205956A0 (en) | A telecommunications network and telecommunications device | |
| IL204672A0 (en) | Steps or plates for a conveying device, and conveying device | |
| HK1098702A1 (en) | A selective androgen receptor modulator and method uses thereof | |
| GB0602251D0 (en) | A magnetorheological device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20190911 |